India rejects Novartis patent bid for cancer drug
A court in India has dismissed a patent bid by the pharmaceutical company Novartis.
The Swiss company wanted to protect its cancer drug Glivec.
Healthcare activists say the ruling ensures that cheaper generic versions of the drug will remain accessible in a country where many patented drugs are too costly for most people.
Shilpa Kannan reports.
02 Apr 2013
- From the section Business